Overview

• Health officials said IMSS and ISSSTE report roughly 97% supply while IMSS‑Bienestar remains lower, with remaining gaps concentrated in undelivered contracts, including oncology lines.
• Companies identified as lagging were given until the end of the month to fulfill deliveries or face debarment and contractual penalties, according to subsecretary Eduardo Clark.
• The government’s list highlights high non‑delivery rates such as Bioxintegral at 100% and Productos Farmacéuticos at 87%, with additional shortfalls cited for firms tied to oncology products.
• President Claudia Sheinbaum acknowledged outstanding debts to suppliers and said payments are being processed, but insisted contracted companies must deliver on time despite arrears.
• Industry groups countered that payment delays and debts of roughly 14,000–40,000 million pesos strain operations, arguing most of the 34 named firms are distributors or foreign companies that bid extremely low without sufficient production capacity.